Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
7TM Pharma
Phase I/II clinical studies initiated for the treatment of obesity
August 10th, 2005
7TM Pharma has started phase I/II clinical trials with TM30338 from its Y receptor program for the treatment of obesity. TM30338 has a novel, unique mode of action and is derived from the company's proprietary platform of Y receptor peptides. 7TM Pharma's Y receptor peptides have been developed using the company's structure-based drug discovery approach as well as expertise specifically within the Y receptor field. Two distinct types of Y receptors have been validated in man as appetite suppressive drug targets using natural hormones. TM30338 is a novel, proprietary compound with improved properties as a drug candidate, which in a single peptide...
Source: Biotech Week (2005-08-10)
|
